{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035988","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.443546+00:00","generated_at":"2026-05-29T19:40:16.996904+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations","bullets":["MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.","Early adoption exceeded expectations; launch within 8–12 weeks post-approval as previously guided.","Indicated in combination with miglustat for neurological NPC in patients aged 2+.","AmplifyAssist patient support program launched to address insurance and access barriers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035988","json":"https://secwatch.observer/filing/0001437749-24-035988.json","markdown":"https://secwatch.observer/filing/0001437749-24-035988.md","text":"https://secwatch.observer/filing/0001437749-24-035988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924035988/0001437749-24-035988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924035988/zvra20241121_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:40:16.996904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}